Sun Pharma Q1 results: Net profit rises 40% to Rs 2,836 cr, revenue up 6%

Q: How long will it take to read this news story?

The story "Sun Pharma Q1 results: Net profit rises 40% to Rs 2,836 cr, revenue up 6%" has 553 words across 20 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Sun Pharma Q1 results: Net profit rises 40% to Rs 2,836 cr, revenue up 6%" was covered 10 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 307 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #21884963</li><li>URL: https://beamstart.com/news/sun-pharma-q1-results-net-17225088966950</li></ul>

Business Standard Logo Business Standard 10h ago

Sun Pharma Q1 results: Net profit rises 40% to Rs 2,836 cr, revenue up 6% - Business Standard

Quick Summary:

On a sequential basis, the company exhibited a 6.8 per cent rise in net profit, while its revenue grew by 5.5 per cent, from Rs 2,655 crore and Rs 12,380.

Dilip Shanghvi, chairman and managing director of Sun Pharma, said that the company has recently attained several milestones with the approval of Leqselvi in the US, the filing of Nidlegy in Europe, and the completion of the acquisition of Taro minority shares.“These steps will advance our innovative as well as generic business offerings and will help us serve patients better,” he added.

It also reported that the company had completed its acquisition of all outstanding ordinary shares of Taro Pharmaceutical Industries, other than the shares already held by the group in the June quarter, for a consideration of $347.7 million.